Details of HTA project
Last updated: 26 August 2008 - Next update due: 2 September 2008
Research type: |
NICE Technology Assessment Report (TAR) |
Project title: |
Bevacizumab, sorafenib, tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic evaluation |
Link to NICE guidance page |
|
Project ref: |
07/72/01 |
Cost: |
This project has been commissioned by the HTA programme on behalf of the National Institute for Health and Clinical Excellence on a call-off contract basis. |
Chief Investigator : |
Peninsula Medical School (PenTAG), University of Exeter |
Start Date: |
October 2007. |
Publication date: |
May 2009. This project is at the editorial review stage. Delays in the review process can cause the forecast publication date to be delayed. |
Plain English Summary |
In England and Wales, around 6,000 people are diagnosed with renal cell cancer each year. In about a third of those, the disease is at an early stage and the tumour is contained entirely within the kidney. For these people the mainstay of treatment is surgical removal of the tumour. However, around a fifth of people do not find out that they have kidney cancer until the tumour is at a more advanced stage and may have spread either to other organs in the body (metastatic disease) or to other tissues surrounding the kidney (locally advanced disease). Surgical removal of these tumours may not be possible and there are currently few other treatment options. The most commonly used therapies are interferon-alpha and interleukin-2 (both are immunotherapy). There are currently no standard treatments for people with metastatic renal cell cancer who do not respond to immunotherapy. Only a small number of people (about 10%) diagnosed with late stage renal cell cancer survive for more than five years from the date of diagnosis. This assessment will review the clinical and cost effectiveness of four new drugs for treating advanced and metastatic renal cell cancer. Bevacizumab (also known as Avastin®) used in combination with interferon-alpha, sorafenib tosylate (also known as Nexavar®), sunitinib (also known as Sutent®) and temsirolimus (also known as Torisel® or CCI-779). All four drugs, although they produce their effects in slightly different ways, aim to stop the tumour growing. The assessment will draw together all the relevant evidence about these drugs systematically and will focus on differences in overall survival, progression-free survival, tumour response rate, health related quality of life and side effects of treatment resulting from the use of bevacizumab, sorafenib tosylate, sunitinib and temsirolimus compared to current standard treatments for advanced and metastatic renal cell cancer. It will also assess whether the treatments are likely to be considered good value for money for the NHS. |
Abstract: |
The purpose of this technology assessment is to appraise the clinical and cost effectiveness of bevacizumab, sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma in line with their marketing authorisations. The NIHR HTA programme commissioned this report on behalf of the National Institute for Health and Clinical Excellence. |
NRR* number, if applicable: |
(*National Research Register) |
Project Protocol: |
Project protocol not available |
URL of this page: |
http://www.hta.ac.uk/1711 |
News feeds